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Abstract Transgenic rabbits carrying gene constructs encoding
human nerve growth factor beta (hNGF-L) cDNA were
generated. Expression of hNGF-L mRNA was restricted to the
mammary gland of lactating rabbits. Western Blot analysis
revealed a polypeptide of 13.2 kDa in the milk of transgenic
animals. hNGF-L was purified from the milk by a two-step
chromatographic procedure. Electrospray mass spectroscopy
analysis of purified hNGF-L depicted a molecular weight of
13 261 Da per subunit. The biological activity of the hNGF-L was
tested using PC12W2 cells and cultures of dorsal root ganglion
neurons from chicken embryos. Crude defatted milk from
transgenic animals and purified hNGF-L demonstrated full
biological activity when compared to commercial recombinant
hNGF-L.
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1. Introduction
Nerve growth factor (NGF), the founder member of a pro-
tein family termed neurotrophins, is known to promote the
survival and di¡erentiation of primary sensory neurons, sym-
pathetic neurons and cholinergic neurons of the basal fore-
brain [1^4]. Several attempts have been undertaken to produce
a large quantity of recombinant hNGF from Escherichia coli
[5], yeast [6], insect cells [7] and mammalian cell cultures [8,9].
Preclinical studies using recombinant hNGF-L to treat neuro-
nal dysfunction of the central and peripheral nervous systems
[10,11] and clinical trials including the treatment of HIV-re-
lated peripheral neuropathy carried out by Genentech Incor-
porated are potential indications for the need of a large quan-
tity of biologically active hNGF-L. In the last 10 years
tremendous progress has been made in increasing yields of
recombinant proteins synthesized by mammalian culture sys-
tems. However, for large-scale production, transgenic technol-
ogies can be considered according to their overall yield [12].
Here, we describe a mammary gland speci¢c expression of
hNGF-L cDNA under the control of the regulatory elements
of the bovine Ks1-casein gene and the secretion of functional
hNGF-L in the milk of transgenic rabbits.
2. Materials and methods
2.1. Generation and analysis of hNGF-L transgenic rabbits
Transgenic rabbits were generated by microinjection of p180 con-
structs (Fig. 1) into fertilized oocytes as described in [13^15]. For the
detection of transgenic animals, PCR analysis of genomic DNA ex-
tracted from ear or tail biopsies using Oligo248 and Oligo249 was
performed (see Fig. 1).
2.2. Analysis of transgenic protein: SDS-PAGE and Western blot
Defatted milk from lactating transgenic and non-transgenic rabbits
was diluted 1:10 with 10 mM Tris-HCl pH8.0/10 mM CaCl2. Diluted
milk (2 Wl) was mixed with 2Usample bu¡er (SDS reducing bu¡er),
heated at 95‡C for 5 min and fractionated on a 15% SDS-PAGE
according to Laemmli [16]. The transfer of proteins to nitrocellulose
membranes (Immobilon NC pure, Millipore, Austria) was performed
according to standard protocols [17]. Detection of hNGF-L was car-
ried out with goat polyclonal anti-hNGF antibodies (RpD Systems,
UK), secondary rabbit anti-goat IgG peroxidase conjugate (Sigma
Immuno Chemical, USA) and chemiluminescence (ECL, Amersham,
UK) according to the manufacturers’ protocols. Recombinant hNGF-
L synthesized in the mouse myeloma cell line NSO (RpD Systems,
UK) was applied as a standard control.
2.3. Analysis of transgenic mRNA expression: RT-PCR
Total RNA was extracted with Trizol (Gibco BRL, Life Technol-
ogies, Austria) from mammary gland biopsies during lactation. First
strand cDNA was synthesized using oligodT in the presence of M-
MLV reverse transcriptase (Gibco BRL, Life Technologies, Austria)
according to standard protocols [17]. Two p180 speci¢c oligonucleo-
tide primers (oligo4 and oligo5) were designed to screen the expression
of hNGF-L (see Fig. 1). For the ampli¢cation control, the expression
of rabbit K-actin was assayed using the following oligonucleotides: 5P-
TGTGACATCGACATCAGGAAGG-3P and 5P-TAGGTAATGA-
GTCAGAGCTTTGG-3P (nt 917^938 and nt 1277^1299, GenBank
accession number X60732).
2.4. Cell culture and bioassays
The biological activity of NGF (enhancing cell survival and induc-
ing neurite outgrowth) was determined using PC12W2 cells cultured
as described in [18,19]. To test for neurite outgrowth, PC12W2 cells
(0.7^1U104 cells/well) were maintained on collagen coated 6-well tis-
sue culture plates (Falcon, Becton Dickinson) in the medium contain-
ing 2% serum (1% inactivated horse serum and 1% inactivated fetal
calf serum). Defatted milk from transgenic and non-transgenic (con-
trol) rabbits was diluted with RPMI 1640 containing antibiotics. Neu-
rite outgrowth was investigated with dose and time dependent experi-
ments. Diluted milk containing rhNGF-L in doses of 1, 2, 5, 10, 25
and 50 ng/ml medium (dose experiment) and a single dose of 50 ng/ml
medium (time experiment) was added to the cells and compared to the
same concentrations of commercial recombinant hNGF-L (RpD Sys-
tems) likewise diluted with RPMI 1640. Untreated cells and cells
treated with non-transgenic milk diluted with RPMI 1640 were used
as standard controls. Fresh medium with or without additive was
added on day 3. On day 6 (dose dependent neurite outgrowth) and
days 2, 4, and 6 (time dependent neurite outgrowth) the cells were
examined and ¢ve microscopic ¢elds were randomly photographed
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using a Nikon Diaphot 300 microscope. Neurite bearing cells were
counted on the negative ¢lms. The bioassays for each concentration of
rhNGF-L as well as for controls were done in triplicate.
The bioassay with primary cultured neuronal cells was performed as
described in [20]. Brie£y, dorsal root ganglion neurons were extracted
from chicken embryos, cultured in F14 medium [1] with 10% horse
serum and antibiotics and then seeded onto poly-ornithine/laminin
coated microtiter plates in the presence or absence of known concen-
trations of rhNGF standard (preparation from E. coli, Boehringer
Mannheim, Penzberg, Germany) or puri¢ed (see below) rhNGF-L
from transgenic rabbits. Neuronal survival was assessed after 48 h
by counting the number of surviving neurons with neurite elongation
under a phase contrast microscope.
2.5. Puri¢cation of rhNGF-L from milk of transgenic rabbits
The skim milk was adjusted to pH 4.5 by addition of 10% acetic
acid and diluted with distilled water (2 vol.). After 3 h incubation at
room temperature the precipitated protein was removed by centrifu-
gation at 17 000Ug for 30 min. The supernatant (whey acid) was
immediately neutralized with 1 M NaOH and clari¢ed by sterile ¢l-
tration (0.20 Wm). The clear ¢ltrate was loaded onto a HiTrap SP
column (Pharmacia Biotech, Freiburg, Germany) which was equili-
brated with 100 mM sodium acetate, pH 6.5. After washing with
equilibration bu¡er, the retained proteins were eluted with a NaCl
gradient to 1 M. The rhNGF-L containing fractions were pooled
and puri¢ed to homogeneity by chromatography on HA Ultrogel
(Biosepra, Schermbeck, Germany) under essentially the same condi-
tions as before. Samples were analyzed by SDS-PAGE using the
Laemmli bu¡er system [16] and by RP-HPLC on a POROS R1/H
(PerSeptive Biosystems, Wiesbaden, Germany) with a linear gradient
ranging from 5 to 80% acetonitrile in 0.1% tri£uoroacetic acid. Con-
centration of pure rhNGF-L was determined by UV spectroscopy
using A1%=1.50 at 280 nm [21].
2.6. Electrospray mass spectroscopy
The RP-HPLC fractions were applied to the mass spectrometer
(API 100 from PE Sciex, Canada) without further preparation. The
mass analyzer was scanned from 1400 to 2400 amu with a step width
of 0.2 amu. The ori¢ce voltage and the £ow rate of analyte solution
were set at 80 V and 5 Wl/min, respectively. The molecular mass
spectrum was obtained by deconvoluting the mass/charge spectrum
with the software Biospec Reconstruct from PE Sciex. The relative
error of mass determination was 0.01%.
3. Results
3.1. Generation of p180 rabbit lines
Four established lines #2047, #2048, #2049 and #5432
were used for hNGF-L production. F0 females #2047 and
#2049 and F1 individuals for all four lines were studied
at the transcriptional as well as the translational level for
hNGF-L (Table 1).
3.2. Secretion of hNGF-L into the milk of transgenic rabbits
A polypeptide of 13.2 kDa corresponding to the molecular
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Fig. 1. Mammary gland speci¢c gene construct p180 (7.2 kb) and the position of primers used for PCR analysis. The structure of this expres-
sion cassette has been described in detail [22]. Here, a 0.717 kb fragment (from Met3121 to Arg118 [38]) of the cDNA encoding the human pre-
pro-NGF-L was inserted as a fusion gene into this expression cassette under the control of bovine Ks1-casein promotor. A 5P UTR (2.9 kb)
consisting of exon 1 (52 bp, left hatched box) and part of intron 1 and 3P UTR (3.6 kb) containing exon 19 (384 bp, right hatched box) and
part of intron 18 are shown. The fusion gene (cross-hatched) comprises bovine Ks1-casein signal peptide sequence (57 bp), the sequence of
hNGF-L cDNA (717 bp) and a short part of bovine Ks1-casein 3P UTR (12 bp). The positions of oligonucleotide primers for detection of
transgenic animals (p180 rabbits) are indicated: oligo248 (5P-GATGCTTCTCTATTCCTCTG-3P, nt 3266^3285 [39], accession number X59856)
and oligo249 (5P-GACCATAACTGTGGAGTCCC-3P, nt 18 442^18 461 [39], accession number X59856). The position of synthetic hNGF-L pri-
mers used to characterize the expression of hNGF-L are also shown as follows: oligo4 (5P-GATCATCAACCCAGCTTGCTC-3P, nt 2140^2161
(exon 1) [39], accession number X59856) and Oligo5 (5P-TGCCATCCATGGTCAGCGCCT-3P, nt 795^815, cDNA sequence of hNGF-L
EMBL [40], accession number X52599). The predicted ampli¢cation product is 692 bp comprising 46 bp of exon 1 at the 5P Ks1-casein sequence
and 646 bp of hNGF-L cDNA. B, BamHI; H, HindIII; E, EcoRI; Bg, BglII, S*, SalI site of the 5P derived from the cloning vector.
Table 1
Established transgenic lines for the production of hNGF-L
Line F0 Expression analysis F1 (females) Expression analysis
RNA Protein Ectopic RNA Protein Ectopic
1 2047 (f) + + 3 7299 + + 3
2 2048 (m) ND ND ND 2211 + + ND
3 2049 (f) + + 3 7255 + + 3
4 5432 (m) ND ND ND 5749 + + ND
5756 + + ND
ND, not determined; f, female; m, male.
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weight of hNGF-L was detected by Western blot in the milk
of the two F0 females, their o¡spring and the o¡spring of the
male founders. The concentration of hNGF-L in the milk of
transgenic rabbits was determined by comparison of Western
blot signals of transgenic milk samples with known concen-
trations of commercial recombinant hNGF-L mixed with non-
transgenic milk. The level of hNGF-L in the milk varied in the
di¡erent transgenic lines from 50 to 250 mg/l (Fig. 2). The
estimated concentrations were con¢rmed by a bioassay (see
below).
3.3. RNA expression analysis of hNGF-L
Expression of hNGF-L mRNA was found in the mammary
gland of all examined lactating transgenic rabbits as shown by
RT-PCR. The PCR products showed the expected size of 692
bp. A lactating non-transgenic rabbit female was used as a
control and did not show any expression of NGF-L (Fig. 3A).
Di¡erent tissues (muscle, heart, lung, liver, pancreas, spleen,
kidney, ovary, parotid gland, cerebrum, cerebellum, submax-
illary gland, and mammary gland) from transgenic rabbits
(2047, 7299 and 7255) secreting 50, 50 and 70 mg/l hNGF-L
in their milk, respectively, were investigated. The expression of
hNGF-L was restricted to the mammary gland of lactating
transgenic rabbits (Fig. 4). Furthermore, the expression anal-
ysis of 2047 (F0) and its F1 o¡spring (7299) was identical
indicating that the lack of ectopic expression in the F0 indi-
vidual is not due to transgene mosaicism. The RT-PCR was
veri¢ed by ampli¢cation of rabbit K-actin and the expected
fragment with 388 bp is shown (Figs. 3B and 4).
3.4. Bioassays
On day 6, cells treated with milk containing 50 ng/ml
hNGF-L exhibited substantial neurite outgrowth, whereas
most cells treated with milk from non-transgenic rabbits as
well as untreated cells died (Fig. 5). Furthermore, neurite out-
growth increased with both dosage and time and the biolog-
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Fig. 2. Protein analysis/Western blotting analysis of milk from
transgenic and non-transgenic rabbits. The samples were processed
and immunodetected as described in Section 2. Commercial re-
combinant from mouse myeloma cell line NSO (RpD Systems,
UK) served as positive control. Lane 1, non-transgenic rabbit; lane
2, 2211, F1 #2048; lane 3, 5749, F1 #5432; lane 4, 5756, F1#
5432; lane 5, 7255, F1 #2049; lane 6, 2049, F0 #2049; lane 7,
7299, F1 #2047; lane 8, 2047, F0 #2047; lane 9, no sample; lanes
10^12, 50 ng, 25 ng, 12.5 ng of commercial rhNGF mixed with
non-transgenic milk.
Fig. 3. RNA analysis/RT-PCR. Total RNA was extracted from lac-
tating non-transgenic and transgenic rabbits and RT-PCRs were
performed as described in Section 2. Ampli¢cation products are
shown on 1.5% agarose gel stained with dimidium bromide. A:
Lane 1, DNA ladder; lane 2, non-template control; lane 3, non-
transgenic rabbit; lane 4, 2211, F1 #2048; lane 5, 5749, F1 #5432;
lane 6, 5756, F1 #5432; lane 7, 7255, F1 #2049; lane 8, 7299, F1
#2047; lane 9, 2049, F0 #2049; lane 10, 2047, F0 #2047. B: Ex-
pression analysis of rabbit K-actin.
Fig. 4. Ectopic expression analysis/RT-PCR. RNA isolated from di¡erent tissues, RT-PCR and gel electrophoresis were performed as previously
described for RT-PCR. Lane 1, DNA ladder; lane 2, non-template control; lane 3, muscle; lane 4, heart; lane 5, lung; lane 6, liver; lane 7,
pancreas; lane 8, spleen; lane 9, kidney; lane 10, ovary; lane 11, parotid gland; lane 12, cerebellum; lane 13, cerebrum; lane 14, submaxillary
gland; lane 15, mammary gland of non-transgenic rabbit; lane 16, mammary gland of p180 transgenic rabbit. A: 7255, F1 #2049; B: 7299, F1
#2047; C: 2047, F0 #2047.
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ical activity of our recombinant hNGF-L was equivalent to
that exhibited by the commercial recombinant hNGF-L. The
results show increased neurite outgrowth in both experiments
for rhNGF-L and commercial rhNGF-L (Fig. 6A,B). In addi-
tion, the biological activity of puri¢ed factor from the milk
was assessed using primary tissue culture (dorsal root gan-
glion neurons) from chicken embryos. Again, the rhNGF-L
from transgenic rabbits (#2047) displayed the same biological
activity as a standard preparation from E. coli (Boehringer
Mannheim, Penzberg, Germany). The neurotrophic activity
was expressed as one half of the maximal stimulation index
(EC50), e.g. 100 pg/ml for rhNGF-L (data not shown).
3.5. Puri¢cation and mass spectroscopy
The rhNGF-L puri¢ed from the milk of transgenic rabbits
by the two-step chromatographic procedure was shown to be
s 95% pure by SDS-PAGE and RP-HPLC (data not shown).
Electrospray mass spectroscopy analyses of puri¢ed hNGF-L
depicts the mass/charge as well as the derived molecular mass
spectrum (Fig. 7). In addition to molecules with a mass of
13 261.3 amu (expected monomeric molecular weight of
rhNGF-L :13 261.1 amu), molecules with a monomeric molec-
ular mass of 13 104.3 amu were detected. This additional mo-
lecular species corresponds to rhNGF-L molecules lacking the
C-terminal arginine (theoretical molecular mass: 13 104.9
amu). Its abundance exceeds the yield of intact rhNGF-L by
a factor of two. In samples puri¢ed with omission of the acid-
ifying step, the truncated species was not detectable (data not
shown). However, preparation without this step is likely to be
hampered by milk components retaining the recombinant pro-
tein. Puri¢ed rhNGF-L from the milk of transgenic rabbits
has the same biological activity as a standard preparation
from E. coli.
4. Discussion
We have used a mammary gland speci¢c expression cassette
containing the cDNA encoding the prepro-hNGF-L under the
control of bovine Ks1-casein regulatory sequences to generate
transgenic rabbits. Four lines were established and studied at
the level of transcription and translation. Stable, lactation
stage and strictly mammary gland speci¢c production of
hNGF-L was found in the milk of all analyzed transgenic
rabbits. The production rate varied in the di¡erent lines
from 50 to 250 mg/l. Several laboratories have reported the
production of biologically active hNGF, e.g. from mammali-
an cell culture 4 mg/l, 2.5 mg/l [8,9], E. coli 2.7 mg/l [5], yeast
1 mg/l [6] and insect cells 20 mg/l [7]. Although our produc-
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Fig. 5. Morphology of PC12W2 cells. PC12W2 cells were cultured as described in Section 2. For the bioassay, cells were washed, maintained
in RPMI/2% serum (1% FCS and 1% horse serum) and treated on days 1 and 3 as described in Section 2. Morphology of PC12W2 cells cul-
tured on day 6 in RPMI/15% serum (A); in RPMI/2% serum in the presence of diluted transgenic milk containing 50 ng/ml medium (B); in
RPMI/2% serum in the presence of the milk from non-transgenic rabbit (C); in RPMI/2% serum (D). Cells were examined under a microscope
and photographed (12U).
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tion rate is much higher than most reported to date, it is
nonetheless lower than expected. Using the same expression
cassette we have recovered 0.1^1 g/l rhIGF-1 [22,23]. Varied
production rates in the milk of transgenic mice were reported
using bovine Ks1-casein regulatory sequences [24]. Variation in
the expression of the gene constructs in transgenic animals
seems to be a common phenomenon which probably depends
on the regulatory elements of promoters, the sequences of the
gene of interest (genomic sequences or cDNA), the integration
sites and the number of integrated copies of the gene of
interest (for detailed discussion and references see [23]).
The established cell line PC12W2 and primary dorsal root
ganglion neurons from chicken embryos were used to assay
the biological activity of non-puri¢ed and puri¢ed rhNGF-L,
respectively. Both systems demonstrated clearly that rhNGF-L
is biologically active in crude milk as well as puri¢ed from the
milk. The biological activity of rhNGF-L in each system was
comparable to that shown by the standard control rhNGF-L.
Rat pheochromocytoma cells (PC12) are a well established
cell line system to test survival and neurite outgrowth in the
presence of NGF [25,18,19]. We show that 6 days of culture
1 ng/ml of rhNGF-L or commercial rhNGF-L is required for
survival but not su⁄cient for di¡erentiation. In contrast, Al-
tar et al. [26] and Schmelzer et al. [9] showed neurite out-
growth in PC12 cells at 39^52 pg/ml and 100^200 pg/ml
rhNGF, respectively. We have observed massive cell death
for untreated cells or cells treated with milk from non-trans-
genic rabbits. Glassman et al. [27] reported that more than
80% of native PC12 cells survived 1 week in 3% serum with-
out NGF. In PC12W2 cells, neurite outgrowth starts at 2 ng/
ml with maximal induction of cell di¡erentiation at 50 ng/ml
medium on day 6 for rhNGF-L as well as for the standard
commercial rhNGF-L. The discrepancies in the bioassays may
be due to the cell line used or the culturing conditions of the
cells. Serum or plasma fractions from p180 rabbits did not
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Fig. 6. Dose and time dependent neurite outgrowth in PC12W2
cells. Cells were maintained in medium containing 2% serum and
rhNGF-L or commercial rhNGF-L was added as described. A: On
day 6 for dose dependent neurite outgrowth in response to diluted
milk containing 1, 2, 5, 10, 25 and 50 ng/ml of rhNGF-L (F) and
commercial rhNGF-L (Std. rhNGF-L) diluted with RPMI (E). B:
Time dependent neurite outgrowth in response to diluted milk con-
taining 50 ng/ml on days 2, 4 and 6 for rhNGF-L (8) and commer-
cial rhNGF-L (50 ng/ml) (E). Five random microscopic ¢elds (mag-
ni¢cation is 10U) were photographed and neurite bearing cells were
counted on the negative ¢lms. Neurite bearing cells were scored as
cells with neurites longer than the cell body. Percent neurite out-
growth was calculated as the number of cells with neuritesU100/to-
tal number of cells counted. Experiments were done in triplicate. Er-
ror bars represent S.E.M. (n = 3).
Fig. 7. Electrospray mass spectroscopy of rhNGF-L prepared from
p180 rabbit (#2047) milk. Top: mass/charge (m/z) spectrum, the
numbers above the peaks correspond to the numbers of protons
bound to analyte molecules. Bottom: molecular mass spectrum ob-
tained by deconvolution of the m/z spectrum. The peaks on the
high mass side of the main peaks are due to the formation of so-
dium adducts during the ionization process.
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induce any neurite outgrowth in PC12W2 cells indicating the
absence of ectopic transgene expression as has been con¢rmed
by RT-PCR analyses. In addition, this suggests the absence of
resorption of hNGF-L from milk to blood at these expression
levels. High expression of hNGF-L mRNA was found exclu-
sively in the mammary gland of lactating transgenic rabbits
(Figs. 3 and 4). Similar results have been reported [22,28,24]
using bovine Ks1-casein regulatory sequences. The transgenic
rabbits did not show any transgene speci¢c detrimental e¡ects
in their physiological or reproductive performance. In con-
trast, speci¢c overexpression of NGF in transgenic mice pro-
duced morphological (hypertrophy and hyperplasia) and func-
tional changes (hyperinnervation) of organs within which the
transgene was expressed [29,30]. Our results show that the
mammary gland of transgenic rabbits is a possible source of
recombinant hNGF-L with the properties of native hNGF-L.
Rabbit husbandry can be carried out under speci¢c pathogen
free conditions and to date no infectious agent pathogenic for
humans, which might be di⁄cult to remove by the puri¢cation
procedure of the recombinant protein, has been found in rab-
bits. rhNGF-L was easily puri¢ed to homogeneity and exhib-
ited the same biological activity as commercial rhNGF-L. The
C-terminal truncation observed by electrospray mass spec-
troscopy analysis has no obvious in£uence on the biological
activity of rhNGF as has been demonstrated previously [9,31].
However, research is in progress to avoid the cleavage of
C-terminal arginine. Studies on the physiology of NGF and
with rhNGF in animal models indicated the bene¢cial e¡ects
of exogenous NGF for the treatment of age dependent neuro-
nal dysfunction [32^35] or peripheral neuropathic diseases
[36,37] in humans.
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